Promising drug cocktail aims to stall aggressive lung cancer
Disease control
Recruiting now
This study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive the drug combo every 21 days for up to 2 years, w…
Phase: PHASE2 • Sponsor: Bindu R Potugari • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC